Immune-mediated diseases and risk of incident cardiovascular diseases: a prospective cohort study

被引:6
作者
Yu, Yuetian [1 ]
Sun, Ying [1 ]
Wang, Yuying [1 ]
Yu, Yuefeng [1 ]
Wang, Bin [1 ]
Chen, Chi [1 ]
Tan, Xiao [2 ,3 ]
Lu, Yingli [1 ]
Wang, Ningjian [1 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Inst & Dept Endocrinol & Metab, Sch Med, Shanghai 200011, Peoples R China
[2] Zhejiang Univ, Sch Publ Hlth, Hangzhou, Peoples R China
[3] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
关键词
immune-mediated diseases; cardiovascular diseases; cohort; UK Biobank; C-REACTIVE PROTEIN; SYSTEMIC-LUPUS-ERYTHEMATOSUS; RHEUMATOID-ARTHRITIS; PSORIATIC-ARTHRITIS; ENDOTHELIAL DYSFUNCTION; INFLAMMATORY DISEASES; ATRIAL-FIBRILLATION; PREVALENCE; EVENTS; STROKE;
D O I
10.1093/rheumatology/kead266
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Disorders of immune system may impact cardiovascular health; however, comprehensive study is lacking. We aimed to analyse the association of total and 20 individual immune-mediated diseases (IMDs) with risk of incident cardiovascular disease (CVD). Methods In this prospective cohort study, 414 495 participants (55.6% women; mean age 55.9 years) from UK Biobank with baseline assessment at 2006-10 were included. Among them, 21 784 participants had prevalent IMDs. Information on IMDs at baseline and incidence of CVDs during follow-up were recorded. Cox proportional hazard models were used to estimate the association between IMDs and CVDs risk. Results During the median follow-up of 12.1 years, there were 6506 cases of CVDs in participants with IMDs (29.9%) and 77 699 cases in those without IMDs (19.8%). After multivariable adjustment, participants with IMDs were significantly associated with an increased risk of total CVD [hazard ratio (HR) 1.57; 95% CI 1.52-1.61]. Among the 20 IMDs, 16 showed significant associations with CVD (all P < 0.0025 after Bonferroni correction), with HR ranging from 1.34 (1.16-1.54) for celiac disease to 2.75 (2.10-3.61) for SLE. Participants with any IMD exposure had a higher risk of all individual CVD events, with HR ranging from 1.34 (1.14-1.58) for cerebral hemorrhage to 1.80 (1.54-2.11) for pericardium diseases. IMD duration <5, 5-10 and >10 years was associated with 55%, 59% and 56% increased risk of total CVD, respectively. Conclusion Total and individual IMDs were associated with an increased risk of overall CVDs. It is important to consider primary prevention of CVD in patients with IMD and dysregulation of immune system in the cardiovascular health.
引用
收藏
页码:706 / 714
页数:9
相关论文
共 50 条
[21]   Psoriasis and Cardiovascular Diseases: An Immune-Mediated Cross Talk? [J].
Orlando, Gloria ;
Molon, Barbara ;
Viola, Antonella ;
Alaibac, Mauro ;
Angioni, Roberta ;
Piaserico, Stefano .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[22]   Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study [J].
Pujades-Rodriguez, Mar ;
Morgan, Ann W. ;
Cubbon, Richard M. ;
Wu, Jianhua .
PLOS MEDICINE, 2020, 17 (12)
[23]   Immune-mediated inflammatory diseases and risk of venous thromboembolism: A Mendelian randomization study [J].
Lv, Xiaoshuo ;
Gao, Xixi ;
Liu, Jingwen ;
Deng, Yisen ;
Nie, Qiangqiang ;
Fan, Xueqiang ;
Ye, Zhidong ;
Liu, Peng ;
Wen, Jianyan .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[24]   Risk of Heart Failure in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Study [J].
Koppikar, Sahil ;
Kuriya, Bindee ;
Udell, Jacob A. ;
Yu, Bing ;
Chu, Anna ;
Lee, Douglas S. ;
Widdifield, Jessica ;
Eder, Lihi .
JOURNAL OF RHEUMATOLOGY, 2025, 52 (05) :489-497
[25]   Genetics of immune-mediated inflammatory diseases [J].
David, T. ;
Ling, S. F. ;
Barton, A. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2018, 193 (01) :3-12
[26]   ADALIMUMAB IN THE TREATMENT OF IMMUNE-MEDIATED DISEASES [J].
Lapadula, G. ;
Marchesoni, A. ;
Armuzzi, A. ;
Blandizzi, C. ;
Caporali, R. ;
Chimenti, S. ;
Cimaz, R. ;
Cimino, L. ;
Gionchetti, P. ;
Girolomoni, G. ;
Lionetti, P. ;
Marcellusi, A. ;
Mennini, F. S. ;
Salvarani, C. .
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2014, 27 :33-48
[27]   Clustering of immune-mediated diseases in sarcoidosis [J].
Terwiel, Michelle ;
Grutters, Jan C. ;
van Moorsel, Coline H. M. .
CURRENT OPINION IN PULMONARY MEDICINE, 2019, 25 (05) :539-553
[28]   Adversities in childhood and young adulthood and incident cardiovascular diseases: a prospective cohort study [J].
Zou, Xia ;
Zhao, Junfei ;
Feng, Anping ;
Chan, Kei Hang Katie ;
Wu, Wen-Chih ;
Manson, JoAnn E. ;
Liu, Simin ;
Li, Jie .
ECLINICALMEDICINE, 2024, 69
[29]   Impact of moderate wine consumption on immune-mediated diseases [J].
Di Lorenzo, Chiara ;
Restani, Patrizia ;
Antoce, Arina Oana ;
Romano, Raquel ;
Fradera, Ursula ;
Teissedre, Pierre-Louis ;
Ruf, Jean-Claude ;
Bani, Corinne ;
Mercogliano, Francesca ;
Araujo, Marcos ;
Kosti, Rena I. .
OENO ONE, 2024, 58 (03)
[30]   Immune-mediated inflammatory diseases and the risk of valvular heart disease: a Mendelian randomization study [J].
Dihui Cai ;
Zequn Zheng ;
Jiale Hu ;
Yin Fu ;
Yongfei Song ;
Jiangfang Lian .
Clinical Rheumatology, 2024, 43 :533-541